Haematologica · 2026
Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Lulu, Fu Haixia, Qin Yazhen, Zhao Xiaosu, Zhao Peng, An Zhuoyu, He Yun, Huang Qiusha, Chen Yuhong, Lv Meng, Kong Jun, Wang Zhidong, Han Wei, Zhang Yuanyuan, Mo Xiaodong, Han Tingting, Yan Chenhua, Chang Yingjun, Wang Fengrong, Zhao Xiangyu, Wang Yu, Xu Lanping, Huang Xiaojun, Zhang Xiaohui
Аннотация
KMT2A partial tandem duplication (KMT2A-PTD) is a recurrent genetic alteration in acute myeloid leukemia (AML), but its role as a measurable residual disease (MRD) marker before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. We retrospectively analyzed 180 KMT2A-PTD AML patients undergoing allo-HSCT at Peking University People's Hospital between 2015 and 2025. Pre-transplant KMT2A-PTD MRD was quantified by real-time quantitative PCR, with positivity defined as ≥1500 copies/10⁵ ABL1. Among 158 patients transplanted in complete remission (CR), 144 had pre-transplant MRD assessment, and 34 (24%) were MRDpositive. Compared with MRD-negative patients, MRD-positive patients had significantly inferior 3- year overall survival (OS, 49% vs. 80%; p.